achieved morphologic and cytogenetic remission after 2 months of treatment with lenalidomide therapy and a second patient who achieved a platelet response after only 1 month of therapy before receiving an unrelated allogeneic stem cell transplant. Both patients remain without any evidence of relapse with a maximum follow-up of 8 months.
Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2 V617F mutation Leukemia (2007) Mutation of JAK2 V617F is currently known to play a potential role in the development of chronic myeloproliferative disorders (CMPD); 1 78% (393/506) of polycythemia vera (PV) cases have JAK2 V617F , while only 43% (55/127) of reported chronic idiopathic myelofibrosis (CIMF) cases have JAK2 V617F . 2 Thus the question naturally arises whether the CIMF patients without JAK2
V617F might have another pathway towards myelofibrosis or a common pathogenic factor may exist with or without the V617F in CMPD using the sequence-specific primer-single molecule fluorescence detection assay, 3 we studied cytogenetic changes in nine patients with CIMF, 51 with essential thrombocythemia (ET) and 34 with PV. Myelofibrosis developed in seven of 51 patients (13.7%) with ET and five of 34 patients (14.7%) with PV, and we compared clinical and cytogenetic changes between patients with CIMF and those with myelofibrosis developing in PV/ET.
The group of patients with myelofibrosis associated with PV/ ET had high incidences of history of thrombosis (4/12 versus 0/9; P ¼ 0.0542), requirement of cytoreductive chemotherapy (12/12 versus 5/9; P ¼ 0.0103) and acute leukemia development (7/12 versus 1/9; P ¼ 0.0274) compared with the CIMF group. Depending on the status of JAK2 V617F , the group of patients with myelofibrosis associated with PV/ET with GT/TT mutation of JAK2 had a high incidence of chemotherapy requirement (10/ 10 versus 2/4; P ¼ 0.0157) and tended to have a frequent thrombosis history (4/10 versus 0/4; P ¼ 0.1345) (Supplementary Table 1 ). However, there was no particular difference in the percentage of abnormal karyotypes at the time of myelofibrosis according to CIMF diagnosis or the mutational status of JAK2 V617F . We also noted a high frequency of myelofibrosis development in patients with JAK2 V617F in PV (wild-type JAK2/heterozygous JAK2 V617F /homozygous JAK2 V617F : 0/9 versus 2/18 versus 3/7: P ¼ 0.0460), but not in ET (2/18 versus 5/30 versus 0/1: P ¼ 0.7970), in agreement with the report by Kralovics et al. 4 In myelofibrosis patients, we noticed that two of the nine patients with CIMF had chromosome abnormalities at the 12q15 region; one had t(1;12)(p34;q15), while the other had t(12;20)(q15;q11?) ( Table 1 and Figure 1 ). Another patient (JAK2_0021) reported as showing t(4;12)(q31;q21) had a prior history of myelodysplastic syndrome (MDS)-refractory anemia with a normal karyotype 6 years before myelofibrosis. Re-assessment by the spectral karyotypic analysis revealed that this anomaly was t(4;12)(q27;q15) (Supplementary Figure 1) . In contrast to the results of CIMF, no patients with myelofibrosis developing from PV/ET had 12q15 anomaly. Of the 12 patients with myelofibrosis associated with PV/ET, four had À7/7qÀ, including two with der(1;7)(q10;p10); both patients with der(1;7)(q10;p10) had a prior ET diagnosis 6 with heterozygous JAK2 V617F ( This case was reported as myelodysplastic syndrome developing myelofibrosis with a 6-year interval; 5 however, the continuity of the disease is uncertain. Bold signifies chromosomal translocations involving 12 of 15 region. Table 1 Continued Case no. Age at diagnosis/sex Cytogenetics at the time of myelofibrosis JAK2 V617F
Figure 1
Partial quinacrine-banded karyotypes obtained from two patients with chronic idiopathic myelofibrosis (JAK2_0048 and JAK2_0163) and one patient with myelofibrosis with prior history of myelodysplastic syndrome (JAK2_0021) showing 12q15 anomalies, that is, t(1;12)(p34;q15), t(12;20)(q15;q11?) and t(4;12)(q27;q15). Arrows indicate possible breakpoint of 12q15.
Letters to the Editor one had homozygous JAK2 V617F ; the 12q15 anomaly was detected in one patient with wild-type JAK2, while two had heterozygous JAK2 V617F . Cytogenetic changes in CIMF are well documented: þ 8, del(20q), À7/7qÀ, del(11q) and del(13q) are known to be recurring nonspecific cytogenetic abnormalities, and some of them are also detectable in PV or ET patients. In the literature, Andrieux et al. 7 reported a possible role in the association between HMGA2 and translocation involving 12q15 in CIMF. In the current study, we found that 12q15 anomaly does not depend on the JAK2 mutational status; thus genetic anomaly, independent to JAK2 V617F , may exist in CIMF, and molecular study on the 12q15 region, including HMGA2, 8 may disclose another pathogenetic pathway in CIMF. The 12q15 chromosomal abnormality was recurrently detected in patients with CIMF, while der(1;7)(q10;p10) was only noted in ET patients who had myelofibrosis with JAK2 V617F . 6 These findings clearly indicate that myelofibrosis among CMPD might be cytogenetically heterogeneous.
